Abbott reports stronger than expected sales

was largely responsible for the surprisingly strong sales - a factor that has also bolstered first-quarter results for Eli Lilly and Johnson & Johnson. Sales of Humira, the company's biggest product, rose 18 per cent to $1.65 billion, a bit higher than...